Sarepta Exercises Option to Acquire Myonexus Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Sarepta Therapeutics (SRPT) PT Raised to $213 at Cowen
February 28, 2019 6:21 AM ESTCowen analyst Ritu Baral raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $213.00 (from $178.00) while maintaining a Outperform rating.
Baral commented, "SRPT reported 4Q18 with pre-announced Exondys revenues only slightly below consensus but meeting FY18 guidance. SRPT provided timeline updates for its... More
Sarepta (SRPT) Phase I/IIa MYO-101 Trial Data 'Striking' - SunTrust
February 27, 2019 11:55 AM ESTSunTrust analyst Edward Nash reiterated a Buy rating and $176 price target on Sarepta Therapeutics (NASDAQ: SRPT) following 'striking' preliminary results from a Phase I/IIa MYO-101 study in Limb-Girdle Muscular Dystrophy Type 2E (LGMD2E) or beta-sarcoglycanopathy, a severe and debilitating form of LGMD characterized by progressive muscle fiber loss,... More
Sarepta Therapeutics (SRPT) Hits Pre-market High, Up 7% with Conference Call Onoing
February 27, 2019 8:16 AM ESTSarepta Therapeutics (NASDAQ: SRPT) Hits Pre-market High, Up 7% with Conference Call Onoing
